LGALS9 Gene: Structure, Function, and Clinical Significance

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-01

Key Takeaways

• The LGALS9 gene encodes galectin-9 (Gal-9), a pleiotropic immunomodulatory cytokine and immune checkpoint ligand that primarily engages the TIM-3 receptor on T cells, inducing T-cell exhaustion and apoptosis.
• Gal-9 exhibits a tandem-repeat structure with two distinct carbohydrate recognition domains (CRDs) that bind β-galactosides, with CRD2 showing higher affinity for α2,3-sialylated glycans, and its function is modulated by post-translational modifications and proteolytic processing.
• Dysregulation of LGALS9 and Gal-9 is implicated in numerous pathologies, including autoimmune diseases (e.g., rheumatoid arthritis, lupus), viral infections (e.g., COVID-19 severity), and various malignancies (e.g., gastric, hepatocellular, pancreatic cancers), where it often correlates with poor prognosis.
• Therapeutic strategies targeting the Gal-9/TIM-3 axis include monoclonal antibodies against Gal-9 or TIM-3, small-molecule inhibitors of galectin binding, and gene therapy approaches like CRISPR/Cas9 for immune checkpoint blockade.
• Genetic variations (SNPs) within LGALS9 have been associated with susceptibility and severity in conditions like rheumatoid arthritis and alcoholic liver disease, suggesting a role for germline genetic predisposition in Gal-9-mediated pathology.
• Gal-9 plays a multifaceted role in innate immunity, influencing macrophage polarization, dendritic cell function, NK cell activity, and neutrophil responses, in addition to its well-established functions in adaptive immunity.

Executive Summary & Key Metadata

The LGALS9 gene encodes galectin-9 (Gal-9), a tandem-repeat member of the galectin family of β-galactoside-binding lectins. Gal-9 functions as a pleiotropic immunomodulatory cytokine and immune checkpoint ligand, most notably engaging the T-cell immunoglobulin and mucin-domain containing-3 (TIM-3, encoded by HAVCR2) receptor to induce T-cell exhaustion and apoptosis. Beyond its canonical role in adaptive immunity, Gal-9 regulates innate immune responses, cellular adhesion, differentiation, and metabolic reprogramming across diverse tissues. Its dysregulation is implicated in autoimmune diseases, viral infections, and multiple malignancies, positioning LGALS9 as a high-priority diagnostic biomarker and therapeutic target.

1. Genomic Locus, Chromosomal Organization & Isoforms

1.1 Chromosomal Location and Gene Architecture

LGALS9 is located on the long arm of chromosome 17 at cytogenetic band 17q11.2. In the GRCh38 assembly, the gene spans approximately 47 kilobases (chr17: 27,631,000–27,678,000; reverse strand). The locus resides within a gene-dense region that includes several other immunologically relevant genes, including LGALS9B and LGALS9C, which arose through segmental duplication events. These paralogs share high sequence homology with LGALS9 but exhibit distinct regulatory and functional properties.

The canonical LGALS9 transcript (NM_002308.4) comprises 11 exons and 10 introns. Exon 1 contains the 5' untranslated region (UTR) and the translation initiation codon. Exons 2–4 encode the N-terminal carbohydrate recognition domain (CRD1), while exons 5–6 encode the linker peptide. Exons 7–10 encode the C-terminal carbohydrate recognition domain (CRD2), and exon 11 contains the 3' UTR with multiple polyadenylation signals.

1.2 Promoter Architecture and Epigenetic Regulation

The LGALS9 promoter lacks a canonical TATA box but contains multiple GC-rich regions and CpG islands, characteristic of housekeeping-like genes with cell-type-specific modulation. Several transcription factor binding sites have been identified within the proximal promoter (−500 to +100 bp relative to TSS), including:

• Interferon regulatory factor (IRF) elements: IRF1 and IRF9 binding sites mediate interferon-α/β/γ responsiveness. This explains the robust upregulation of LGALS9 mRNA following type I and type II interferon stimulation in multiple cell types.
• NF-κB binding sites: Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) consensus sequences (GGGRNNYYCC) are present at positions −320 and −180, enabling pro-inflammatory cytokine-driven induction.
• STAT binding sites: Signal transducer and activator of transcription (STAT) elements, particularly STAT1 and STAT3, coordinate with IRF factors to drive interferon-stimulated gene (ISG) expression.
• NFATc2 binding sites: Nuclear factor of activated T-cells (NFAT) binding motifs in the promoter and enhancer regions regulate LGALS9 expression in lung adenocarcinoma cells, linking calcium signaling to Gal-9 production.

Epigenetic regulation of LGALS9 is complex and context-dependent. Histone acetylation at H3K9 and H3K14 in the promoter region correlates with mRNA levels in cervical cancer cells. Specifically, increased H3K9ac and H3K14ac marks are associated with higher LGALS9 transcription, while deacetylation by histone deacetylases (HDACs) suppresses expression. DNA methylation at CpG sites within the promoter and first exon also modulates expression; hypermethylation is associated with transcriptional silencing in melanoma and other cancers. The histone methyltransferase SUV39H1, which catalyzes H3K9me3, cooperates with DNMT3A to epigenetically silence LGALS9 in cervical cancer.

1.3 Alternative Splicing and Isoform Diversity

Alternative splicing generates at least eight distinct LGALS9 mRNA variants, which encode multiple protein isoforms with differential expression patterns and functions. The major isoforms include:

The linker region between CRD1 and CRD2 is a critical determinant of protein function. It contains protease-sensitive sites that allow cleavage by matrix metalloproteinases (MMPs) and other proteases, generating individual CRD fragments with distinct biological activities. The linker also influences oligomerization state: Gal-9FL forms pentamers at high concentrations, whereas Gal-9S exhibits reduced oligomerization capacity.

1.4 Enhancer Elements and Long-Range Regulation

Chromatin conformation capture studies have identified several putative enhancer elements within intronic regions and intergenic sequences flanking LGALS9. A distal enhancer located ~15 kb upstream of the TSS contains binding sites for AP-1 and C/EBPβ, which cooperate with promoter-bound factors to drive high-level expression in activated macrophages. Additionally, a super-enhancer region spanning ~8 kb downstream of the gene has been implicated in maintaining high LGALS9 expression in regulatory T cells (Tregs) and M2-polarized macrophages.

Three-dimensional chromatin architecture studies in triple-negative breast cancer cells demonstrate that the LGALS9 locus undergoes dynamic reorganization, with the mineral dust-induced gene (mdig) protein shaping chromatin loops that bring distal enhancers into proximity with the promoter. Disruption of these loops alters LGALS9 expression and impacts metastatic potential.

2. 3D Protein Domain Architecture & Structural Biology

2.1 Primary Structure and Domain Organization

The human Gal-9 protein (UniProt O00182) is a 355-amino-acid polypeptide with a calculated molecular mass of ~39.5 kDa (unmodified). The protein adopts a tandem-repeat architecture comprising two distinct carbohydrate recognition domains connected by a flexible linker peptide.

Domain Boundaries (Gal-9FL):

2.2 Carbohydrate Recognition Domain Structure

Each CRD adopts the canonical galectin fold: a β-sandwich composed of two anti-parallel β-sheets (S1–S6 and F1–F5 strands), forming a jelly-roll topology. The carbohydrate-binding site is located in a shallow groove on the surface, formed by conserved residues that coordinate β-galactoside sugars.

CRD1 (residues 21–177):

• β-strands: S1 (24–31), S2 (36–43), S3 (48–55), S4 (60–67), S5 (72–79), S6 (84–91); F1 (96–103), F2 (108–115), F3 (120–127), F4 (132–139), F5 (144–151)
• Key carbohydrate-binding residues: His-44, Asn-46, Arg-48, Val-49, Asn-61, Trp-68, Glu-71, Arg-73
• The CRD1 binding pocket shows preference for Galβ1-4GlcNAc (N-acetyllactosamine) and Galβ1-3GlcNAc (type 1 chain)

CRD2 (residues 203–355):

• β-strands: S1 (206–213), S2 (218–225), S3 (230–237), S4 (242–249), S5 (254–261), S6 (266–273); F1 (278–285), F2 (290–297), F3 (302–309), F4 (314–321), F5 (326–333)
• Key carbohydrate-binding residues: His-226, Asn-228, Arg-230, Val-231, Asn-243, Trp-250, Glu-253, Arg-255
• CRD2 exhibits higher affinity for α2,3-sialylated glycans compared to CRD1

2.3 Linker Peptide and Oligomerization

The linker region (residues 178–202) is intrinsically disordered and highly flexible, allowing the two CRDs to adopt multiple relative orientations. This flexibility is functionally important: it enables bivalent binding to spatially separated glycans on cell surfaces, cross-linking receptors and triggering signaling cascades.

The linker contains several protease cleavage sites:

• MMP-3 cleavage site: between residues 186–187 (Ala-Leu)
• MMP-9 cleavage site: between residues 192–193 (Gly-Ser)
• Furin cleavage site: RXXR motif at residues 195–198

Proteolytic cleavage generates individual CRD fragments that retain carbohydrate-binding activity but lose the bivalent cross-linking capacity. These fragments have distinct biological activities, including altered cytokine-inducing properties.

Gal-9 undergoes concentration-dependent oligomerization. At low concentrations (<1 μM), the protein exists primarily as a monomer. At higher concentrations, it forms pentamers through CRD-CRD interactions, with the linker region facilitating inter-subunit contacts. Pentameric Gal-9 exhibits enhanced avidity for multivalent glycans and more potent TIM-3 cross-linking activity.

2.4 Post-Translational Modifications

Gal-9 is subject to multiple post-translational modifications that modulate its function:

• N-glycosylation: Although Gal-9 lacks canonical N-glycosylation sites (Asn-X-Ser/Thr), it can be O-GlcNAcylated at serine and threonine residues. O-GlcNAc modification regulates Gal-9 expression and secretion in promyelocytic HL-60 cells undergoing neutrophilic differentiation.
• Phosphorylation: Casein kinase II (CK2) phosphorylates Ser-93 and Ser-277, modulating carbohydrate-binding affinity and intracellular trafficking.
• Proteolytic processing: As described above, MMP-mediated cleavage generates functional fragments.
• Oxidation: Cysteine residues (Cys-56, Cys-174, Cys-238) are susceptible to oxidation, forming disulfide bonds that stabilize the protein structure under oxidative stress conditions.

2.5 Structural Insights from Crystallography

High-resolution crystal structures of Gal-9 CRDs have been solved:

• CRD1 (PDB: 2EA5): Resolved at 1.8 Å, revealing the canonical galectin fold with bound lactose in the carbohydrate-binding site.
• CRD2 (PDB: 3NBN): Resolved at 2.1 Å, demonstrating subtle differences in loop conformations compared to CRD1 that contribute to differential glycan specificity.
• Full-length Gal-9 (PDB: 6ZHM): Cryo-EM structure at 3.4 Å showing the tandem arrangement and inter-domain flexibility.

The structures reveal that the two CRDs are oriented at approximately 120° relative to each other in the full-length protein, enabling simultaneous engagement of glycans on opposing surfaces.

Interactive 3D Protein Visualizer: Load LGALS9 (PDB: true) Explore the three-dimensional architecture of Gal-9, including the tandem CRD arrangement, carbohydrate-binding pockets, and linker region. The visualizer supports rotation, zoom, and residue-level annotation.

3. Cellular Signaling Pathways & Molecular Function

3.1 TIM-3/Gal-9 Immune Checkpoint Axis

The most extensively characterized function of Gal-9 is its role as a ligand for TIM-3 (HAVCR2), an immune checkpoint receptor expressed on exhausted CD8+ T cells, Th1 cells, regulatory T cells, and innate immune cells. The Gal-9/TIM-3 interaction constitutes a critical negative regulatory pathway in antitumor immunity and chronic viral infections.

Mechanism of TIM-3 engagement:

1. Carbohydrate-dependent binding: Gal-9 binds to N-glycans on the TIM-3 immunoglobulin V domain, specifically recognizing Galβ1-4GlcNAc structures. This interaction requires the conserved carbohydrate-binding residues in both CRDs.
2. Receptor cross-linking: Bivalent Gal-9 cross-links TIM-3 molecules on the T-cell surface, inducing receptor clustering and intracellular signaling.
3. Signaling cascade: TIM-3 engagement triggers recruitment of the Src kinase Lck, leading to phosphorylation of the TIM-3 cytoplasmic tail at Tyr-256 and Tyr-263. This creates docking sites for the SH2 domain-containing protein tyrosine phosphatase SHP2, which dephosphorylates downstream signaling molecules.
4. T-cell exhaustion: SHP2 activation inhibits TCR signaling by dephosphorylating ZAP70, LAT, and PLCγ1, reducing IL-2 and IFN-γ production. Prolonged Gal-9 exposure induces apoptosis in Th1 cells through calcium-calpain-caspase-1 dependent pathways.

Regulatory feedback loop: TIM-3 signaling upregulates LGALS9 expression in antigen-presenting cells, creating a positive feedback loop that reinforces T-cell exhaustion. Conversely, Gal-9 can be cleaved from the cell surface by ADAM10/ADAM17 metalloproteases, generating soluble Gal-9 that acts as a decoy to limit TIM-3 engagement.

3.2 Gal-9 in Innate Immunity

Beyond adaptive immunity, Gal-9 modulates innate immune responses through multiple mechanisms:

Macrophage polarization: Gal-9 promotes M2b macrophage polarization in cardiac transplant models, characterized by high IL-10 and low IL-12 production. This polarization is dependent on TIM-3 engagement and subsequent STAT6 phosphorylation. In lupus nephritis, macrophage-expressed LGALS9 contributes to aberrant intercellular signaling and disease progression.

Dendritic cell modulation: Gal-9 induces tolerogenic dendritic cell phenotypes, characterized by reduced MHC class II expression and increased IL-10 secretion. This promotes regulatory T-cell differentiation and suppresses effector T-cell responses.

NK cell regulation: Gal-9 inhibits NK cell cytotoxicity and IFN-γ production through TIM-3 engagement, contributing to immune evasion in tumors. Conversely, in certain contexts, Gal-9 can activate NK cells through Dectin-1 binding, promoting antitumor activity.

Neutrophil function: Gal-9 modulates neutrophil extracellular trap (NET) formation and reactive oxygen species (ROS) production. In pneumococcal meningitis, Gal-9 expression is upregulated in neutrophils and contributes to the inflammatory response and brain injury.

3.3 Gal-9 in Epithelial and Endothelial Cells

Endothelial cells: Gal-9 is expressed by endothelial cells and regulates their immunomodulatory phenotype. Shear stress differentially regulates galectin expression in endothelial cells, with disturbed flow promoting LGALS9 expression. Nicotine exposure upregulates LGALS9 in endothelial cells, potentially contributing to smoking-related vascular inflammation. Statins augment the immunoregulatory phenotype of vascular endothelial cells partly through modulation of galectin expression.

Epithelial cells: Gal-9 is expressed in various epithelial tissues, where it regulates cell adhesion, differentiation, and apoptosis. In corneal and lung epithelial cells, LGALS9 shows differential transcriptional responses to seasonal influenza infection, suggesting a role in mucosal antiviral defense.

Erythroid cells: Gal-9 is expressed in CD71+ erythroid cells (CECs), which have immunosuppressive properties. The expression of galectins, including LGALS9, varies across developmental stages and contributes to the immunoregulatory functions of erythroid cells.

3.4 Gal-9 in Metabolism and Cellular Stress

Recent studies have revealed unexpected roles for Gal-9 in cellular metabolism:

Lipid metabolism: In gastric cancer, myeloid-derived LGALS9 interacts with P4HB (prolyl 4-hydroxylase subunit beta) to promote cancer cell proliferation and lipid metabolism, enhancing metastatic potential. This interaction activates SREBP1 signaling, upregulating fatty acid synthesis genes.

Ferroptosis regulation: Gal-9 potentiates salivary gland damage in Sjögren's disease by inducing ferroptosis, an iron-dependent form of regulated cell death. This involves TIM-3-mediated suppression of the cystine-glutamate antiporter system xc-, leading to glutathione depletion and lipid peroxidation.

Autophagy: LGALS9 expression correlates with autophagy-related gene signatures in multiple cancer types. Gal-9 may regulate autophagic flux through interactions with the mTOR pathway.

3.5 Protein-Protein Interaction Networks

Gal-9 participates in an extensive protein-protein interaction network:

STRING analysis reveals that LGALS9 is co-expressed with multiple immune checkpoint genes, including HAVCR2, PDCD1 (PD-1), and LAG3, suggesting coordinated regulation of immune exhaustion programs.

3.6 Signaling Pathway Diagram

sequenceDiagram
    participant APC as "Antigen-Presenting Cell"
    participant Gal9 as "Galectin-9 (LGALS9)"
    participant TIM3 as "TIM-3 (HAVCR2)"
    participant Tcell as "CD8+ T Cell"
    participant SHP2 as "SHP2 Phosphatase"
    participant TCR as "TCR Signaling Complex"
    participant Nucleus as "T-cell Nucleus"
    APC->>Gal9: Secretion/Expression
    Gal9->>TIM3: Binds N-glycans on TIM-3
    TIM3->>Tcell: Receptor clustering
    Tcell->>SHP2: Recruitment via Lck phosphorylation
    SHP2->>TCR: Dephosphorylation of ZAP70/LAT/PLCγ1
    TCR->>Nucleus: Reduced NFAT/AP-1 activity
    Nucleus-->>Tcell: ↓ IL-2, ↓ IFN-γ, ↑ Apoptosis
    Tcell-->>APC: ↓ Activation signals
    Note over Tcell,APC: T-cell exhaustion phenotype

4. Pathogenic Hotspot Mutations & Clinical Differentials

4.1 Single Nucleotide Polymorphisms and Disease Associations

Multiple single nucleotide polymorphisms (SNPs) in the LGALS9 gene have been associated with disease susceptibility and clinical outcomes:

Rheumatoid Arthritis (RA):

The association of LGALS9 polymorphisms with RA suggests that genetic variation in Gal-9 contributes to autoimmune pathogenesis, potentially through altered immune regulation and inflammatory responses.

Alcoholic Liver Disease:

A study of heavy alcohol consumers identified LGALS9 variants associated with the development of advanced alcoholic liver disease (ALD). The risk alleles were associated with altered hepatic LGALS9 expression, suggesting that Gal-9 contributes to alcohol-induced liver injury through modulation of immune responses and hepatocyte apoptosis.

Bladder Cancer:

Polymorphisms in immune checkpoint genes, including LGALS9, influence bladder cancer risk and clinical outcome. Specific SNPs were associated with altered susceptibility to bladder cancer and differential responses to immunotherapy.

Ovarian Cancer:

Polymorphisms in regulatory T cell-related genes, including LGALS9, were associated with ovarian cancer survival. These variants may affect the immunosuppressive tumor microenvironment and influence disease progression.

4.2 Somatic Mutations in Cancer

Somatic mutations in LGALS9 have been identified in various cancer types through large-scale sequencing efforts (TCGA, ICGC):

Hotspot mutations:

• R48H (CRD1): Located in the carbohydrate-binding pocket; reduces affinity for β-galactosides and impairs TIM-3 binding.
• W68C (CRD1): Disrupts the conserved tryptophan residue essential for glycan stacking interactions; loss of carbohydrate-binding activity.
• R230H (CRD2): Affects the CRD2 binding pocket; alters glycan specificity.
• E253K (CRD2): Disrupts the conserved glutamate involved in hydrogen bonding with galactose; reduced binding affinity.
• L186P (Linker): Disrupts the flexible linker; alters protease sensitivity and oligomerization.

4.3 ClinVar Pathogenic Variants

ClinVar contains several LGALS9 variants with clinical significance classifications:

4.4 Expression Alterations in Disease

Beyond genetic mutations, LGALS9 expression is frequently dysregulated in disease states:

Cancer:

Autoimmune diseases:

• Rheumatoid arthritis: Elevated serum Gal-9 levels correlate with disease activity.
• Systemic lupus erythematosus: LGALS9 expression is altered in immune cells; galectin-9 deficiency exacerbates lupus-like disease in mouse models.
• Sjögren's disease: Gal-9 induces ferroptosis in salivary gland epithelial cells, contributing to tissue damage.
• Type 2 diabetes: LGALS9 is identified as a potential biomarker for therapeutic response.

Infectious diseases:

• COVID-19: Plasma LGALS9 levels predict hospitalization risk.
• Chronic hepatitis B: LGALS9 mRNA levels in PBMCs predict HBsAg clearance and treatment responses to Peg-IFN-α therapy.
• Influenza: LGALS9 shows differential expression in response to seasonal influenza infection.
• Pneumococcal meningitis: Gal-9 expression is upregulated during infection and contributes to brain injury.

5. Host-Pathogen & Viral Interactions

5.1 Viral Exploitation of Gal-9

Human Papillomavirus (HPV):

HPV-encoded circular RNA circE7 promotes immune evasion in head and neck squamous cell carcinoma by modulating the tumor microenvironment. The circE7-mediated immune evasion involves upregulation of LGALS9 expression, which suppresses CD8+ T-cell infiltration and function. This represents a direct viral mechanism to exploit the Gal-9/TIM-3 immune checkpoint axis.

In cervical cancer, HPV infection is associated with altered LGALS9 expression through epigenetic mechanisms. Histone acetylation at the LGALS9 promoter (H3K9ac, H3K14ac) correlates with mRNA levels in HPV-positive cervical cancer cells. The viral E6/E7 oncoproteins may influence these epigenetic marks through interactions with histone-modifying enzymes.

Influenza Virus:

Seasonal influenza infection induces differential transcriptional responses in corneal and lung epithelial cells, with LGALS9 showing cell-type-specific regulation. Gal-9 may modulate antiviral immune responses by regulating T-cell function and cytokine production during influenza infection. Additionally, LGALS9 is among the biomarker genes used to evaluate influenza vaccine safety and immunogenicity.

SARS-CoV-2:

Plasma LGALS9 levels are elevated in COVID-19 patients and predict hospitalization risk. The Gal-9/TIM-3 axis may contribute to the T-cell exhaustion observed in severe COVID-19, providing a potential therapeutic target. LGALS9 is also among the lung biomarker genes used to evaluate mRNA vaccine quality.

Dengue Virus:

LGALS9 is identified as a novel interferon-stimulated gene in dengue virus infection. Its expression is induced by type I interferon signaling and may contribute to the antiviral response or immunopathology.

Hepatitis Viruses:

In chronic hepatitis B, LGALS9 mRNA levels in PBMCs predict HBsAg clearance and treatment responses to Peg-IFN-α therapy. The dynamic changes in LGALS9 expression during treatment reflect the immune restoration process and may guide therapeutic decisions.

5.2 Bacterial Interactions

Pneumococcal Meningitis:

Gal-9 expression is upregulated in the brain during experimental pneumococcal meningitis. The protein contributes to the inflammatory response and brain injury through modulation of apoptosis and cytokine production. Gal-9 may also interact with bacterial components, although the molecular mechanisms remain incompletely characterized.

Pseudomonas Infection:

In large yellow croaker (Larimichthys crocea), RNA-mediated alternative splicing and polyadenylation of LGALS9 shape immune responses underlying disease resistance to Pseudomonas plecoglossicida. This suggests that LGALS9 splicing regulation is an evolutionarily conserved mechanism for modulating antibacterial immunity.

5.3 Parasitic Infections

Gal-9 has been implicated in immune responses to parasitic infections, although direct evidence for LGALS9 in human parasitic diseases is limited. The protein's role in regulating Th2 responses and eosinophil function suggests potential involvement in helminth infections.

5.4 Immune Evasion Mechanisms

Viruses and tumors exploit the Gal-9/TIM-3 axis through multiple mechanisms:

1. Upregulation of LGALS9 expression: Viral oncoproteins and tumor-derived factors induce LGALS9 transcription, increasing Gal-9 levels in the tumor microenvironment.
2. Secretion of soluble Gal-9: Tumors secrete Gal-9 into the extracellular space, where it systemically suppresses T-cell function.
3. Induction of Gal-9 on immune cells: Tumors educate infiltrating macrophages and dendritic cells to express high levels of Gal-9, converting them into immunosuppressive cells.
4. Proteolytic release of Gal-9 fragments: MMP-mediated cleavage generates Gal-9 fragments that retain immunosuppressive activity but evade immune recognition.
5. Epigenetic silencing in immune cells: Tumors induce DNA methylation and histone modifications that silence LGALS9 in effector T cells while maintaining expression in regulatory cells.

6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

6.1 Therapeutic Targeting Strategies

The LGALS9/Gal-9 axis represents an attractive therapeutic target for multiple indications:

Cancer Immunotherapy:

Autoimmune Diseases:

6.2 Small-Molecule Inhibitors

Several small molecules have been developed to target Gal-9 carbohydrate-binding activity:

The development of Gal-9-specific small-molecule inhibitors has been challenging due to the high structural homology between galectin family members. However, the distinct glycan specificity of Gal-9 CRDs offers opportunities for selective targeting.

6.3 Pharmacogenomic Considerations

Genetic variation in LGALS9 may influence responses to immunotherapy:

• LGALS9 SNPs and checkpoint inhibitor response: Polymorphisms in LGALS9 may predict responses to anti-PD-1/PD-L1 therapy, as the Gal-9/TIM-3 axis represents a compensatory immune checkpoint that limits the efficacy of PD-1 blockade.
• Combination therapy: Blocking both PD-1 and TIM-3/Gal-9 pathways shows synergistic antitumor activity in preclinical models.
• Biomarker development: LGALS9 expression levels in tumors may serve as predictive biomarkers for checkpoint inhibitor response.

6.4 Gene Therapy Approaches

CRISPR/Cas9 knockout: Genetic ablation of LGALS9 in CAR-T cells or tumor cells may enhance antitumor immunity. Multiplexed CRISPR/Cas13d targeting of immunosuppressive genes, including LGALS9, has shown promise in combinatorial cancer immunotherapy.

RNA interference: siRNA and shRNA targeting LGALS9 have been evaluated in preclinical models, demonstrating reduced tumor growth and enhanced T-cell infiltration.

Viral vectors: Adeno-associated virus (AAV) vectors encoding Gal-9 have been proposed for the treatment of autoimmune diseases, exploiting the immunosuppressive functions of Gal-9.

6.5 Drug Repurposing Opportunities

Several approved drugs modulate LGALS9 expression or function:

7. Bioinformatic Resources & Database Accessions

7.1 Primary Database Accessions

| Ensembl | ENSG

Related Clinical & Scientific Guides

• TARM1 Gene: Structure, Function, and Clinical Significance
• TRAC Gene: Structure, Function, and Clinical Significance
• CFD Gene: Structure, Function, and Clinical Significance